+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pulmonary Drug Delivery Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026

  • ID: 4852027
  • Report
  • August 2018
  • Region: Global
  • 346 pages
  • Transparency Market Research
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now

Global Pulmonary Drug Delivery Devices Market: Overview

The pulmonary route of administration has proven to be effective in local and systemic delivery of miscellaneous drugs and biopharmaceuticals to treat pulmonary and non-pulmonary diseases. Inhalation therapy is the best option to treat to treat lung diseases such as asthma and cystic fibrosis. The global pulmonary drug delivery devices market is expanding at a significant pace due to factors such as increase in incidence of lung diseases and rise in digitalization of inhaler devices, which offers convenience to patients.

The global pulmonary drug delivery devices market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on product, application, distribution channel, and region. A detailed qualitative analysis of drivers, restraints, and opportunities has been provided in the market overview section. Additionally, the section comprises competitive matrix and company profiles to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by geography and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global pulmonary drug delivery devices market.

Global Pulmonary Drug Delivery Devices Market: Key Segments

In terms of product, the global pulmonary drug delivery devices market has been segmented into dry powder inhalers, metered dose inhalers, and nebulizers. The dry powder inhalers segment has been further sub-segmented into single dose inhalers, and multi-dose inhalers. The metered dose inhalers segment has been further split into total manually-actuated pressurized inhaler and breath-actuated pressurized inhaler. The nebulizers segment has been further sub-segmented into jet nebulizers, ultrasonic wave nebulizers, and vibrating mesh nebulizers. The product segment has been analyzed based on different type of devices uses to treat different pulmonary diseases in various regions. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. In terms of application, the global pulmonary drug delivery devices market has been segregated into asthma, COPD, cystic fibrosis, and others. In term of end-user, the global pulmonary drug delivery devices market has been classified into retail pharmacies, hospital pharmacies, and e-commerce. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the period from 2018 to 2026, considering 2017 as the base year.

Global Pulmonary Drug Delivery Devices Market: Regional Outlook

The global pulmonary drug delivery devices market has been segmented into five major regions and key countries/sub-regions in the respective region are: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC, South Africa, Israel, and Rest of MEA). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2016 to 2026, along with their respective CAGRs for the period from 2018 to 2026, considering 2017 as the base year. The research study also provides the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles major players in the market in terms of various attributes such as company overview, financial overview, devices portfolios, business strategies, and recent developments. Major companies profiled in the global pulmonary drug delivery devices market include GlaxoSmithKline plc, Boehringer Ingelheim GmbH, AstraZeneca plc, Koninklijke Philips N.V., 3M Healthcare, Omron Corporation, F. Hoffmann-La Roche Ltd., Novartis AG, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., MannKind Corporation, Mylan N.V., Sunovion Pharmaceuticals, Inc., PARI GmbH, and Nypro Healthcare Inc. (Jabil Circuit Inc.) The global pulmonary drug delivery devices market has been segmented as follows:

Global Pulmonary Drug Delivery Devices Market, by Product

  • Dry Powder Inhalers
    • Single Dose Inhalers
    • Multi-dose Inhalers
  • Metered Dose Inhalers
    • Manually-actuated Pressurized Inhaler
    • Breath-actuated Pressurized Inhaler
  • Nebulizers
    • Jet Nebulizers
    • Ultrasonic Wave Nebulizers
    • Vibrating Mesh Nebulizers

Global Pulmonary Drug Delivery Devices Market, by Application

  • Asthma
  • COPD
  • Cystic Fibrosis
  • Others

Global Pulmonary Drug Delivery Devices Market, by Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • E-commerce

Global Pulmonary Drug Delivery Devices Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Israel
    • Rest of Middle East & Africa
Note: Product cover images may vary from those shown
2 of 2
Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary: Global Pulmonary Drug Delivery Devices Market

Chapter 4. Market Overview
4.1. Introduction
4.1.1. Product Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Global Pulmonary Drug Delivery Devices Market Analysis and Forecasts, 2016-2026
4.3.1. Global Pulmonary Drug Delivery Devices Market Revenue Projection Value (US$ Mn) and Volume (Million Units)
4.4. Global Pulmonary Drug Delivery Devices Market Outlook
4.4.1. Porter’s Analysis
4.4.2. Value Chain Analysis
4.4.3. Pipeline Analysis
4.4.4. Pipeline Snapshot of Key Clinical Analytics Therapies

Chapter 5. Global Pulmonary Drug Delivery Devices Market Analysis and Forecasts, by Product
5.1. Key Findings/Developments
5.2. Introduction & Definition
5.3. Global Pulmonary Drug Delivery Devices Market Value and Volume Forecast, by Product, 2017-2026
5.3.1. Dry Powder Inhalers
5.3.1.1. Single Dose Inhalers
5.3.1.2. Multi-dose Inhalers
5.3.2. Metered Dose Inhalers
5.3.2.1. Manually-actuated Pressurized Inhalers
5.3.2.2. Breath-actuated Pressurized Inhalers
5.3.3. Nebulizers
5.3.3.1. Jet Nebulizers
5.3.3.2. Ultrasonic Wave Nebulizers
5.3.3.3. Vibrating Mesh Nebulizers
5.4. Global Pulmonary Drug Delivery Devices Market Attractiveness, by Product

Chapter 6. Global Pulmonary Drug Delivery Devices Market Analysis and Forecasts, by Application
6.1. Key Findings/Developments
6.2. Introduction & Definition
6.3. Global Pulmonary Drug Delivery Devices Market Value and Volume Forecast, by Application, 2017-2026
6.3.1. Asthma
6.3.2. COPD
6.3.3. Cystic Fibrosis
6.3.4. Others
6.4. Global Pulmonary Drug Delivery Devices Market Attractiveness, by Application

Chapter 7. Global Pulmonary Drug Delivery Devices Market Analysis and Forecasts, by Distribution Channel
7.1. Key Findings/Developments
7.2. Introduction & Definition
7.3. Global Pulmonary Drug Delivery Devices Market Value and Volume Forecast, by Distribution Channel, 2017-2026
7.3.1. Retail Pharmacies
7.3.2. Hospital Pharmacies
7.3.3. E-commerce
7.4. Global Pulmonary Drug Delivery Devices Market Attractiveness, by Distribution Channel

Chapter 8. Global Pulmonary Drug Delivery Devices Market Analysis and Forecasts, by Region
8.1. Geographical Representation
8.2. Global Pulmonary Drug Delivery Devices Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region

Chapter 9. North America Pulmonary Drug Delivery Devices Market Analysis and Forecast (Value & Volume)
9.1. North America Pulmonary Drug Delivery Devices Market Value and Volume Forecast, by Country, 2017-2026
9.1.1. U.S.
9.1.2. Canada
9.2. North America Pulmonary Drug Delivery Devices Market Value Share Analysis, by Product, 2017-2026
9.3. North America Pulmonary Drug Delivery Devices Market Value and Volume Forecast, by Product, 2016-2026
9.3.1. Dry Powder Inhalers
9.3.1.1. Single Dose Inhalers
9.3.1.2. Multi-dose Inhalers
9.3.2. Metered Dose Inhalers
9.3.2.1. Manually-actuated Pressurized Inhalers
9.3.2.2. Breath-actuated Pressurized Inhalers
9.3.3. Nebulizers
9.3.3.1. Jet Nebulizers
9.3.3.2. Ultrasonic Wave Nebulizers
9.3.3.3. Vibrating Mesh Nebulizers
9.4. North America Pulmonary Drug Delivery Devices Market Value Share Analysis, by Application, 2017-2026
9.5. North America Pulmonary Drug Delivery Devices Market Value and Volume Forecast, by Application, 2016-2026
9.5.1. Asthma
9.5.2. COPD
9.5.3. Cystic Fibrosis
9.5.4. Others
9.6. North America Pulmonary Drug Delivery Devices Market Value Share Analysis, by Distribution Channel, 2017-2026
9.7. North America Pulmonary Drug Delivery Devices Market Value and Volume Forecast, by Distribution Channel, 2016-2026
9.7.1. Retail Pharmacies
9.7.2. Hospital Pharmacies
9.7.3. E-commerce
9.8. North America Pulmonary Drug Delivery Devices Market Attractiveness Analysis
9.8.1. By Country
9.8.2. By Product
9.8.3. By Application
9.8.4. Distribution Channel

Chapter 10. Europe Pulmonary Drug Delivery Devices Market Analysis and Forecast (Value & Volume)
10.1. Europe Pulmonary Drug Delivery Devices Market Value and Volume Forecast, by Country/Sub-region, 2017-2026
10.1.1. Germany
10.1.2. France
10.1.3. U.K.
10.1.4. Spain
10.1.5. Italy
10.1.6. Rest of Europe
10.2. Europe Pulmonary Drug Delivery Devices Market Value Share Analysis, by Product, 2017-2026
10.3. Europe Pulmonary Drug Delivery Devices Market Value Forecast, by Product, 2016-2026
10.3.1. Dry Powder Inhalers
10.3.1.1. Single Dose Inhalers
10.3.1.2. Multi-dose Inhalers
10.3.2. Metered Dose Inhalers
10.3.2.1. Manually-actuated Pressurized Inhalers
10.3.2.2. Breath-actuated Pressurized Inhalers
10.3.3. Nebulizers
10.3.3.1. Jet Nebulizers
10.3.3.2. Ultrasonic Wave Nebulizers
10.3.3.3. Vibrating Mesh Nebulizers
10.4. Europe Pulmonary Drug Delivery Devices Market Value Share Analysis, by Application, 2017-2026
10.5. Europe Pulmonary Drug Delivery Devices Market Value and Volume Forecast, by Application, 2016-2026
10.5.1. Asthma
10.5.2. COPD
10.5.3. Cystic Fibrosis
10.5.4. Others
10.6. Europe Pulmonary Drug Delivery Devices Market Value Share Analysis, by Distribution Channel, 2017-2026
10.7. Europe Pulmonary Drug Delivery Devices Market Value and Volume Forecast, by Distribution Channel, 2016-2026
10.7.1. Retail Pharmacies
10.7.2. Hospital Pharmacies
10.7.3. E-commerce
10.8. Europe Pulmonary Drug Delivery Devices Market Attractiveness Analysis
10.8.1. By Country/Sub-region
10.8.2. By Product
10.8.3. By Application
10.8.4. Distribution Channel

Chapter 11. Asia Pacific Pulmonary Drug Delivery Devices Market Analysis and Forecast (Value & Volume)
11.1. Asia Pacific Pulmonary Drug Delivery Devices Market Value and Volume Forecast, by Country/Sub-region, 2017-2026
11.1.1. China
11.1.2. Japan
11.1.3. India
11.1.4. Australia & New Zealand
11.1.5. Rest of Asia Pacific
11.2. Asia Pacific Pulmonary Drug Delivery Devices Market Value Share Analysis, by Product, 2017-2026
11.3. Asia Pacific Pulmonary Drug Delivery Devices Market Value Forecast, by Product, 2016-2026
11.3.1. Dry Powder Inhalers
11.3.1.1. Single Dose Inhalers
11.3.1.2. Multi-dose Inhalers
11.3.2. Metered Dose Inhalers
11.3.2.1. Manually-actuated Pressurized Inhalers
11.3.2.2. Breath-actuated Pressurized Inhalers
11.3.3. Nebulizers
11.3.3.1. Jet Nebulizers
11.3.3.2. Ultrasonic Wave Nebulizers
11.3.3.3. Vibrating Mesh Nebulizers
11.4. Asia Pacific Pulmonary Drug Delivery Devices Market Value Share Analysis, by Application, 2017-2026
11.5. Asia Pacific Pulmonary Drug Delivery Devices Market Value and Volume Forecast, by Application, 2016-2026
11.5.1. Asthma
11.5.2. COPD
11.5.3. Cystic Fibrosis
11.5.4. Others
11.6. Asia Pacific Pulmonary Drug Delivery Devices Market Value Share Analysis, by Distribution Channel, 2017-2026
11.7. Asia Pacific Pulmonary Drug Delivery Devices Market Value and Volume Forecast, by Distribution Channel, 2016-2026
11.7.1. Retail Pharmacies
11.7.2. Hospital Pharmacies
11.7.3. E-commerce
11.8. Asia Pacific Pulmonary Drug Delivery Devices Market Attractiveness Analysis
11.8.1. By Country/Asia Pacific
11.8.2. By Product
11.8.3. By Application
11.8.4. Distribution Channel

Chapter 12. Latin America Pulmonary Drug Delivery Devices Market Analysis and Forecast (Value & Volume)
12.1. Latin America Pulmonary Drug Delivery Devices Market Value and Volume Forecast, by Country/Sub-region, 2017-2026
12.1.1. Brazil
12.1.2. Mexico
12.1.3. Rest of Latin America
12.2. Latin America Pulmonary Drug Delivery Devices Market Value Share Analysis, by Product, 2017-2026
12.3. Latin America Pulmonary Drug Delivery Devices Market Value Forecast, by Product, 2016-2026
12.3.1. Dry Powder Inhalers
12.3.1.1. Single Dose Inhalers
12.3.1.2. Multi-dose Inhalers
12.3.2. Metered Dose Inhalers
12.3.2.1. Manually-actuated Pressurized Inhalers
12.3.2.2. Breath-actuated Pressurized Inhalers
12.3.3. Nebulizers
12.3.3.1. Jet Nebulizers
12.3.3.2. Ultrasonic Wave Nebulizers
12.3.3.3. Vibrating Mesh Nebulizers
12.4. Latin America Pulmonary Drug Delivery Devices Market Value Share Analysis, by Application, 2017-2026
12.5. Latin America Pulmonary Drug Delivery Devices Market Value and Volume Forecast, by Application, 2016-2026
12.5.1. Asthma
12.5.2. COPD
12.5.3. Cystic Fibrosis
12.5.4. Others
12.6. Latin America Pulmonary Drug Delivery Devices Market Value Share Analysis, by Distribution Channel, 2017-2026
12.7. Latin America Pulmonary Drug Delivery Devices Market Value and Volume Forecast, by Distribution Channel, 2016-2026
12.7.1. Retail Pharmacies
12.7.2. Hospital Pharmacies
12.7.3. E-commerce
12.8. Market Attractiveness Analysis
12.8.1. By Country/Sub-region
12.8.2. By Product
12.8.3. By Application
12.8.4. Distribution Channel

Chapter 13. Middle East & Africa Pulmonary Drug Delivery Devices Market Analysis and Forecast (Value & Volume)
13.1. Middle East & Africa Pulmonary Drug Delivery Devices Market Value and Volume Forecast, by Country/Sub-region, 2017-2026
13.1.1. GCC
13.1.2. South Africa
13.1.3. Israel
13.1.4. Rest of Middle East & Africa
13.2. Middle East & Africa Pulmonary Drug Delivery Devices Market Value Share Analysis, by Product, 2017-2026
13.3. Middle East & Africa Pulmonary Drug Delivery Devices Market Value Forecast, by Product, 2016-2026
13.3.1. Dry Powder Inhalers
13.3.1.1. Single Dose Inhalers
13.3.1.2. Multi-dose Inhalers
13.3.2. Metered Dose Inhalers
13.3.2.1. Manually-actuated Pressurized Inhalers
13.3.2.2. Breath-actuated Pressurized Inhalers
13.3.3. Nebulizers
13.3.3.1. Jet Nebulizers
13.3.3.2. Ultrasonic Wave Nebulizers
13.3.3.3. Vibrating Mesh Nebulizers
13.4. Middle East & Africa Pulmonary Drug Delivery Devices Market Value Share Analysis, by Application, 2017-2026
13.5. Middle East & Africa Pulmonary Drug Delivery Devices Market Value and Volume Forecast, by Application, 2016-2026
13.5.1. Asthma
13.5.2. COPD
13.5.3. Cystic Fibrosis
13.5.4. Others
13.6. Middle East & Africa Pulmonary Drug Delivery Devices Market Value Share Analysis, by Distribution Channel, 2017-2026
13.7. Middle East & Africa Pulmonary Drug Delivery Devices Market Value and Volume Forecast, by Distribution Channel, 2016-2026
13.7.1. Retail Pharmacies
13.7.2. Hospital Pharmacies
13.7.3. E-commerce
13.8. Middle East & Africa Pulmonary Drug Delivery Devices Market Attractiveness Analysis
13.8.1. By Country/Sub-region
13.8.2. By Product
13.8.3. By Application
13.8.4. Distribution Channel

Chapter 14. Competition Landscape
14.1. Company Market Share Analysis
14.2. Competition Matrix
14.3. Company Profiles (Details - Overview, Financials, Recent Developments, Strategy)
14.3.1. Boehringer Ingelheim GmbH (HQ, Business Segments, Employee Strength)
14.3.1.1. Company Details
14.3.1.2. Company Description
14.3.1.3. Business Overview
14.3.1.4. SWOT Analysis
14.3.1.5. Financial Analysis
14.3.1.6. Strategic Overview
14.3.2. Novartis AG (HQ, Business Segments, Employee Strength)
14.3.2.1. Company Details
14.3.2.2. Company Description
14.3.2.3. Business Overview
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. GlaxoSmithKline plc (HQ, Business Segments, Employee Strength)
14.3.3.1. Company Details
14.3.3.2. Company Description
14.3.3.3. Business Overview
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. AstraZeneca plc (HQ, Business Segments, Employee Strength)
14.3.4.1. Company Details
14.3.4.2. Company Description
14.3.4.3. Business Overview
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Teva Pharmaceutical Industries Ltd. (HQ, Business Segments, Employee Strength)
14.3.5.1. Company Details
14.3.5.2. Company Description
14.3.5.3. Business Overview
14.3.5.4. SWOT Analysis
14.3.5.5. Financial Analysis
14.3.5.6. Strategic Overview
14.3.6. Merck & Co., Inc. (HQ, Business Segments, Employee Strength)
14.3.6.1. Company Details
14.3.6.2. Company Description
14.3.6.3. Business Overview
14.3.6.4. SWOT Analysis
14.3.6.5. Financial Analysis
14.3.6.6. Strategic Overview
14.3.7. MannKind Corporation (HQ, Business Segments, Employee Strength)
14.3.7.1. Company Details
14.3.7.2. Company Description
14.3.7.3. Business Overview
14.3.7.4. SWOT Analysis
14.3.7.5. Financial Analysis
14.3.7.6. Strategic Overview
14.3.8. F. Hoffmann-La Roche Ltd. (HQ, Business Segments, Employee Strength)
14.3.8.1. Company Details
14.3.8.2. Company Description
14.3.8.3. Business Overview
14.3.8.4. SWOT Analysis
14.3.8.5. Financial Analysis
14.3.8.6. Strategic Overview
14.3.9. Mylan N.V. (HQ, Business Segments, Employee Strength)
14.3.9.1. Company Details
14.3.9.2. Company Description
14.3.9.3. Business Overview
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
14.3.10. Omron Corporation (HQ, Business Segments, Employee Strength)
14.3.10.1. Company Details
14.3.10.2. Company Description
14.3.10.3. Business Overview
14.3.10.4. SWOT Analysis
14.3.10.5. Strategic Overview
14.3.11. 3M Healthcare (HQ, Business Segments, Employee Strength)
14.3.11.1. Company Details
14.3.11.2. Company Description
14.3.11.3. Business Overview
14.3.11.4. SWOT Analysis
14.3.11.5. Strategic Overview
14.3.12. Sunovion Pharmaceuticals, Inc. (HQ, Business Segments, Employee Strength)
14.3.12.1. Company Details
14.3.12.2. Company Description
14.3.12.3. Business Overview
14.3.12.4. SWOT Analysis
14.3.12.5. Strategic Overview
14.3.13. Koninklijke Philips N.V. (HQ, Business Segments, Employee Strength)
14.3.13.1. Company Details
14.3.13.2. Company Description
14.3.13.3. Business Overview
14.3.13.4. SWOT Analysis
14.3.13.5. Strategic Overview
14.3.14. PARI GmbH (HQ, Business Segments, Employee Strength)
14.3.14.1. Company Details
14.3.14.2. Company Description
14.3.14.3. Business Overview
14.3.14.4. SWOT Analysis
14.3.14.5. Strategic Overview
14.3.15. Nypro Healthcare Inc. (Jabil Circuit Inc.) (HQ, Business Segments, Employee Strength)
14.3.15.1. Company Details
14.3.15.2. Company Description
14.3.15.3. Business Overview
14.3.15.4. SWOT Analysis
14.3.15.5. Strategic Overview
Note: Product cover images may vary from those shown
Adroll
adroll